Toggle navigation
Home
Medical
Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
27-1-2021
Medical
https://www.medscape.com/cx/rssfeeds/2700.xml
140
Longer-term results from a pivotal study have established ibritinib as one of the most effective monotherapies for this disease. Medscape Medical News
Share
Tweet
+1
Read The Rest
at : https://www.medscape.com/cx/rssfeeds/2700.xml
Related News
Scientists Discover New Protein That Helps Sperms Fuse...
WPATH Removes Age Limits From Transgender Treatment...
Abortion Laws Jeopardize Cancer Treatment for Pregnant...
Study identifies a promising target for polycystic kidney...
Sex Matters in Treatment Outcomes for Pulmonary Embolism
Dry Mouth: Causes and Treatment
Microneedling beats chemical peels for acne scar treatment
Clinical trial sets stage for new paradigm in kidney...
Research examines barriers to treatment of COVID-19 in...
Coronavirus Update (COVID19) - We are open for emergency...